Tisgenx
Tisgenx is a privately held Irvine, California-based medical device company that develops bovine pericardial tissue patches for surgical repair and reconstruction across cardiothoracic, vascular, urology, and general surgery applications, commercialized globally through distributor networks.
- Company typePrivate
- Founded2017
- HeadquartersIrvine, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Tisgenx does
Tisgenx is a privately held medical device company headquartered in Irvine, California, that develops and commercializes bovine pericardial tissue patches for surgical repair and reconstruction. The company markets four branded product lines: Invengenx® for cardiothoracic surgery (including VSD repair, RVOT reconstruction, and truncus arteriosus repair), Vascugenx® for vascular procedures (including aortic aneurysm repair and carotid endarterectomy), Urogenx® for urological applications (including urethroplasty and Peyronie's repair), and Surgenx™ for general surgery soft tissue repair. All products are built on the company's proprietary elixPTM tissue fixation technology, a modified glutaraldehyde-based crosslinking process designed to reduce antigenicity while preserving natural collagen structure, flexibility, and mechanical strength.
The company's core technical differentiator is the elixPTM fixation methodology, which the company claims accelerates endothelialization, mitigates patch shrinkage and aneurysm formation, and produces a highly biocompatible crosslinked collagen matrix. Tisgenx holds FDA 510(k) clearance, CE Mark certification, and ISO certification, enabling commercial distribution in the United States and European Union. The company claims a cumulative footprint of 70 hospitals supplied, 20 certified doctors using its products, and 968 patients treated.
Tisgenx operates an indirect go-to-market model, selling exclusively through a global distributor network that serves hospital networks and surgical centers worldwide. The company actively recruits new distributors and provides clinical training, IFU documentation, and scientific publications to support surgeon adoption. The team is described as having 20+ years of combined experience in the bovine pericardial tissue patch industry. No public revenue figures, funding rounds, or institutional investors are disclosed, and the company appears to be founder-owned and independently financed.
Tisgenx firmographics
Firmographics- Name
- Tisgenx
- Legal name
- Tisgenx, Inc.
- Website
- https://tisgenx.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Tisgenx is a privately held Irvine, California-based medical device company that develops bovine pericardial tissue patches for surgical repair and reconstruction across cardiothoracic, vascular, urology, and general surgery applications, commercialized globally through distributor networks.
- Ownership category
- akta.pro rank
Tisgenx industry classification
Industry- Product category
- Bovine Pericardial Tissue Patches
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)
- akta.pro secondary industries
- Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis) (HLAAAGAJ), Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)
Keywords
Where Tisgenx is headquartered
LocationHeadquarters
- HQ city
- Irvine
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Tisgenx business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Bovine Pericardial Tissue Patch Sales: One-time product sales of medical device patches (Invengenx for cardiothoracic, Vascugenx for vascular, Urogenx for urology, Surgenx for general surgery) to hospitals and surgical centers through distributor network.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Quote-based pricing for medical institutions |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
Tisgenx product offering
Product offeringCore offering
Tisgenx designs, manufactures, and sells bovine pericardial tissue patches crosslinked with its proprietary elixPTM fixation technology for use in surgical repair and reconstruction. The portfolio includes Invengenx for cardiothoracic surgery, Vascugenx for vascular procedures, Urogenx for urology, and Surgenx for general surgery, sold to hospitals and certified surgeons worldwide through a global distributor network.
Product overview
Tisgenx is a medical device company offering a portfolio of bovine pericardial tissue patch products for surgical repair and reconstruction across four therapeutic areas: Invengenx® for cardiothoracic surgery, Vascugenx® for vascular procedures, Urogenx® for urology, and Surgenx™ for general surgery. All products utilize the company's proprietary elixPTM tissue fixation technology, a modified glutaraldehyde-based crosslinking method that creates highly biocompatible, flexible, and durable collagen matrices for various surgical applications.
Differentiator
Problem solved
Functional benefit
Products and services
- Invengenx®
Quantifiable outcome
- 968 satisfied patients treated
Companies that use Tisgenx
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles4 records
Tisgenx technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Tisgenx partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Global Hospital NetworkscoreTisgenx partners with hospital networks globally to distribute their bovine pericardial tissue patches. The company is committed to bridging affordability and performance to benefit hospitals, surgeons, and patients.
Scale indicators4 records
Recent moves5 records
Expansion highlights4 records
Tisgenx competitors and assessment
Company assessmentDirect peers
- Edwards Lifesciences: Major medical device company with a portfolio of bovine pericardial bioprosthetic products used in cardiac and vascular surgery. Directly competes with Tisgenx's Invengenx and Vascugenx patches in the same surgical settings with overlapping surgeon customers.
- LeMaitre Vascular: Specialist in vascular surgical products including biologic and bovine pericardial patches acquired via the Admedus transaction. Competes directly with Tisgenx's Vascugenx and offers overlapping technology platforms in vascular reconstruction.
- Artivion: Cardiovascular tissue company (formerly CryoLife) supplying cardiac and vascular patches, including bovine pericardial tissue products. Direct competitor to Tisgenx in cardiothoracic and vascular repair applications.
Emerging players
- Xeltis: Developer of bioabsorbable restorative cardiovascular devices including potential patch applications. Represents an emerging alternative technology that could compete with Tisgenx's bovine pericardial patches in cardiac surgery over time.
- Admedus: Australia-based developer of biologic patches using proprietary ADAPT tissue engineering technology. Direct competitor in bovine/equine pericardial patches for cardiac and vascular repair, though now partially integrated with LeMaitre.
- Aroa Biosurgery: New Zealand-based regenerative tissue company producing soft-tissue repair products derived from ovine forestomach matrix. Competes with Tisgenx in general surgical soft tissue and wound repair applications.
Broad incumbents
- Baxter International: Large diversified medical device and biopharmaceutical company with surgical and regenerative medicine product lines including tissue patches. Competes with Tisgenx in broader surgical repair markets rather than as a niche specialist.
- Integra LifeSciences: Regenerative tissue technology company with dermal regeneration templates and surgical reconstruction products. Competes with Tisgenx's Surgenx and Urogenx lines in soft tissue repair and reconstruction procedures.
- WL Gore & Associates: Manufacturer of GORE-TEX surgical patches and other implantable biomaterials used in cardiovascular and general surgery. Competes with Tisgenx via a synthetic alternative rather than a biologic tissue approach.
Others
- LifeNet Health: Non-profit tissue bank providing biologic grafts and allograft tissues for surgical reconstruction. Adjacent supplier/distributor in the biologic tissue space that influences the broader market in which Tisgenx competes.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Tisgenx social profiles
Digital presenceTisgenx financial estimates
Financial estimateRevenue estimate
Valuation estimate
Tisgenx leadership team
Management profileNumber of profiles
Tisgenx funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Tisgenx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Tisgenx
What does Tisgenx do?
Tisgenx designs, manufactures, and sells bovine pericardial tissue patches crosslinked with its proprietary elixPTM fixation technology for use in surgical repair and reconstruction. The portfolio includes Invengenx for cardiothoracic surgery, Vascugenx for vascular procedures, Urogenx for urology, and Surgenx for general surgery, sold to hospitals and certified surgeons worldwide through a global distributor network.
Is Tisgenx a public or private company?
Tisgenx is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Tisgenx founded?
Tisgenx was founded in 2017. It employs 1 to 10 people.
Where is Tisgenx based?
Tisgenx is headquartered in Irvine, United States, in the North America region.
How does Tisgenx make money?
One revenue line is on record: bovine Pericardial Tissue Patch Sales.
Who are Tisgenx's main competitors?
Direct peers on record are Edwards Lifesciences, LeMaitre Vascular and Artivion. Emerging players are Xeltis, Admedus and Aroa Biosurgery. Broad incumbents are Baxter International, Integra LifeSciences and WL Gore & Associates. LifeNet Health is listed as an others.
Does Tisgenx have an API?
No public API is recorded for Tisgenx.
What industry is Tisgenx in?
Tisgenx's product category is Bovine Pericardial Tissue Patches. Its primary akta.pro industry code is HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts), with a secondary code of HLAAAGAJ, Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis). Its NAICS code is 339113 and its SIC code is 3841.